WeVote
Log In

Bill

Bill

LD 675

An Act To Protect Consumers By Increasing Transparency And Accountability In The Pharmaceutical Industry

132nd Legislature (2025-2026) Introduced by Joe Baldacci

Failed Maine bill would have increased pharmaceutical industry transparency and consumer protections through enhanced disclosure and accountability requirements.

Pursuant to Joint Rule 310.3 Placed in Legislative Files (DEAD)
#healthcareservices #pharmacies #regulation
0
WeVote Research Nonpartisan
Bill Summary · LD 675

Legislative bill overview

LD 675 sought to increase transparency and accountability measures within Maine's pharmaceutical industry, likely addressing drug pricing, marketing practices, or disclosure requirements. The bill was introduced by Governor Joe Baldacci but failed to advance, receiving an "Ought Not to Pass" (ONTP) recommendation from committee on May 15, 2025, and was ultimately placed in legislative files as dead on May 21, 2025.

Why is this important

Pharmaceutical transparency legislation directly affects consumers' access to affordable medications and their ability to make informed healthcare decisions. Such measures can influence drug pricing practices, reduce hidden costs, and potentially impact pharmaceutical company operations and profits—making this a contentious policy area balancing consumer protection against industry concerns.

Potential points of contention

  • Industry opposition: Pharmaceutical companies may argue that increased transparency and accountability requirements raise compliance costs, potentially limiting drug development investment or increasing medication prices
  • Scope and enforceability: Disagreement likely existed over what information should be disclosed, to whom, and what penalties would apply for non-compliance
  • Regulatory burden: Concerns that state-level pharmaceutical regulations could create inconsistent requirements across jurisdictions, complicating nationwide operations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.